ClinicalTrials.gg
Status unknownNCT04987736Updated Aug 3, 2021

Assessment of Long-term Effects (Complications) of COVID-19 in the Southern Part of Bangladesh - a Retrospective Observational Study.

An observational study in To Assess Long-term Effects of COVID-19 in Patients Who Were Affected With COVID -19, sponsored by Sher-E-Bangla Medical College. Status unknown at 1 site in Bangladesh. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-03.

Sponsored by Sher-E-Bangla Medical College · Observational

How we know

The sponsor has not verified this record recently (last verified Aug 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
302
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in COVID-19 with a site in Bangladesh — none open to participants now, none under way, none of them phase 3. COVID-19 · Bangladesh.

Started
2021
with 6 others
Observational
8 of 32
none open now
Registered
28th of 32
by date
Lead sponsor
2 of 32
Sher-E-Bangla Medical College

Among the 32 studies in COVID-19 with a site in Bangladesh, this one is one of 7 that started in 2021, is one of 8 observational ones, and was the 28th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 32 studies in COVID-19 with a site in Bangladesh is open now. The open studies under COVID-19, anywhere →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 20 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 32 studies in COVID-19 with a site in Bangladesh as a file.
02

Study summary

An outbreak of the novel coronavirus nCoV-19 (SARS-CoV-2), responsible for the coronavirus disease-19 (COVID-19), was first detected in Hubei province, Wuhan, China, on December 31, 2019. It has rapidly spread globally with approximately 157,343,044 confirmed cases and 3,278,510 deaths till 7th May, 2021 [1]. World Health Organization (WHO) declared COVID- 19 pandemic on 11th March 2020.

The world is facing the second wave of Coronavirus Disease 2019 (COVID-19) pandemic which is the most troublesome challenge to public health. The second wave is running and nobody knows where we are in the course of this disease. It becomes a significant challenge for the public health, science, and medical sectors [2].

According to the World Health Organization, about 80% of infections are mild or asymptomatic, 15% result in moderate to severe symptoms (requiring oxygen) and about 5% are critical infections, which require ventilation.

We are learning something new every day. Our understanding of the pandemic is growing and changing daily. The world is focusing on the short term - flattening the curve, treating the sick and discovering a vaccine. But there is more to this pandemic than the short term.

We know a lot about the transmission and clinical feature of COVID-19, but relatively little about what happens after someone recovers. Much is still unknown about how COVID-19 will affect people over time. There's still much to be learned from those who have recovered from COVID-19.

Read the detailed description

B. INTRODUCTION:

An outbreak of the novel coronavirus nCoV-19 (SARS-CoV-2), responsible for the coronavirus disease-19 (COVID-19), was first detected in Hubei province, Wuhan, China, on December 31, 2019. It has rapidly spread globally with approximately 157,343,044 confirmed cases and 3,278,510 deaths till 7th May, 2021 [1]. World Health Organization (WHO) declared COVID- 19 pandemic on 11th March 2020.

The world is facing the second wave of Coronavirus Disease 2019 (COVID-19) pandemic which is the most troublesome challenge to public health. The second wave is running and nobody knows where we are in the course of this disease. It becomes a significant challenge for the public health, science, and medical sectors [2].

According to the World Health Organization, about 80% of infections are mild or asymptomatic, 15% result in moderate to severe symptoms (requiring oxygen) and about 5% are critical infections, which require ventilation.

We are learning something new every day. Our understanding of the pandemic is growing and changing daily. The world is focusing on the short term - flattening the curve, treating the sick and discovering a vaccine. But there is more to this pandemic than the short term.

We know a lot about the transmission and clinical feature of COVID-19, but relatively little about what happens after someone recovers. Much is still unknown about how COVID-19 will affect people over time. There's still much to be learned from those who have recovered from COVID-19.

We are still only one year and four months beyond the first emergence of COVID-19, so it's too early to tell what the extent of any long-term impacts will be.

Most people who have COVID-19 recover completely within a few weeks [3]. But some people - even those who had mild disease, continue to experience symptoms after their initial recovery. Older people and people with many serious medical conditions like diabetes, COPD, heart disease, kidney disease etc. are the most likely to experience these lingering COVID-19 symptoms. The most common symptoms that linger over weeks, even months are:

  • Fatigue
  • Cough (dry)
  • Shortness of breath
  • Headache
  • Joint pain
  • Muscle pain
  • Confusion and even hallucinations. But, our body has surprising healing capacity; most of these symptoms will improve by six months. However, some people recovering from COVID-19 will likely suffer from long-term health problems.

Although COVID-19 is seen as a disease that primarily affects the lungs, it can damage many other organs as well. This organ damage may increase the risk of long-term health problems. Some of the most common long-term effects are:

Lungs: The pneumonia associated with COVID-19 can often cause long-standing damage to the tiny air sacs (alveoli) in the lungs [4]. The resulting scar tissue i.e. pulmonary fibrosis can lead to long-term breathing problems.

Heart: A recent study from the University of Frankford in Germany showed abnormal heart findings in more than 75% of people studied who had recently recovered from COVID-19. Imaging tests taken months after recovery from COVID-19 have shown lasting damage to the heart muscle, even in people who experienced only mild COVID-19 symptoms. This may increase the risk of heart failure or other heart complications in the future.

Brain: COVID-19 can cause strokes [5], seizures and Guillain-Barre syndrome, even in young people. COVID-19 may also increase the risk of developing Parkinson's disease and Alzheimer's disease.

Blood clots and blood vessel problems: COVID-19 can predispose to form clots. While large clots can cause heart attacks and strokes, much of the heart damage caused by COVID-19 is believed to stem from very small clots that block tiny blood vessels (capillaries) in the heart muscle. Other organs affected by blood clots include the lungs, legs, liver and kidneys.

Psychiatric issues: Most people recovering from COVID-19 experience anxiety, depression, or cognitive impairment. Some may develop more serious Post-Traumatic Stress Disorder (PTSD) due to the trauma of the illness and treatment [6].

Kidney: Patient may develop kidney complications which could lead to a need for long-term dialysis.

A lot of things may happen in long run in those who recovered from COVID-19. Our understanding of COVID-19's long term effects will depend greatly on ongoing studies over the next decades.

C. OBJECTIVES:

  1. General Objectives:

    To assess long-term effects of COVID-19 in patients who were affected with COVID -19 (RT-PCR +ve) from 1st July to 30th December, 2020 recorded in PCR Lab of Sher-E-Bangla Medical College Hospital, Barishal i.e. six months or more before the initiation of study and recovered fully.

  2. Specific Objective:

To detect the system-based complications and assess their incidence, and compare the results with other studies in home and abroad.

D. METHODOLOGY:

Study Design: An observational retrospective study. Study Population: COVID -19 (RT-PCR +ve) patients from 1st July to 30th December, 2020 recorded in PCR Lab of Sher-E-Bangla Medical College Hospital, Barishal.

Inclusion Criteria:

  • COVID-19 (RT-PCR +ve) patients age 20 years and above.
  • Those patients whose mobile numbers are recorded in the register.
  • Those patients who/their attendants are available on mobile phone.

Exclusion Criteria:

  • Persons below 20 years of age.
  • Those patients whose mobile numbers are not recorded in the register.
  • Those patients who/their attendants are not available on mobile phone.
  • Those who died by this time from causes unrelated to COVID-19.

Sample Size (n):

To determine the sample size the following formula was followed n= n= the desired sample size z= Standard normal deviate usually set at 1.96 p= Proportion in the population; if not known, it is regarded as 0.5 (50.0%), here p is 0.27 q= 1-p d= Degree of accuracy which is considered as 0.05 According to this formula the targeted sample was 302. But attempt will be taken to take more sample population as far as possible.

Sampling Technique:

Simple random sampling.

Place of Study:

Sher-E-Bangla Medical College Barishal Bangladesh.

Time-frame \& Duration:

6 months from 1st July to 30th December 2021.

Research Instrument:

  1. Record register of PCR lab
  2. Printed questionnaire
  3. Mobile phone
  4. Prescription of registered doctor if any
  5. Investigations if any.

Case definition:

  1. Long-term effects of COVID-19 are those complications which develop or persist after 6 (six) months of COVID-19.
  2. System-based complications should follow the standard definition and are listed in the questionnaire.

Statistical Analysis:

Statistical analyses will be carried out by using the Statistical Package for Social Sciences version 23 for Windows (SPSS Inc., Chicago, Illinois, USA). The mean and Standard deviation values will be calculated for continuous variables. t- test and analysis of variance (ANOVA) will be employed for continuous data. P values \<0.05 was considered as statistically significant.

E. PROCEDURE:

The proposed study will be conducted in Sher-E-Bangla Medical College, Barishal, Bangladesh. Those who were RT-PCR positive for corona in PCR Lab of Sher-E-Bangla Medical College, Barishal from 1st July to 30th December, 2020 and recovered fully, will be listed from register of PCR Lab and their contact numbers will be collected from there. They will be contacted via cell phone and information will be collected after initial exchange of wellbeing and verbal consent. The conversation will be conducted by a registered physician as per prescribed questionnaire. If any complication is reported, then that will be confirmed either by the diagnosis of a registered physician (if already seen) or the patient will be advised to come and confirmed by respective specialist according to complication and specific investigation (if available). Follow-up will be done for at least 6 months after 6 months from the date of RT-PCR +ve by 3 telphonic conversation. All information will be registered in data collection form and analysed thereafter.

F. QUALITY CONTROL:

The quality control of this study will be supervised under the guidance of Professor Khan AK Azad, Ex. Principal, Professor and Head of the Department of Medicine, Dhaka Medical College, Dhaka under the SOP (Standard Operative Procedure).

G. INSTITUTIOAL APPROVAL:

We have already taken the institutional clearance from chairman, ethical committee, Sher-E-Bangla Medical College, Barishal, Bangladesh.

H. BUDGET:

Total Budget: BDT 3,50,000 (Approximately).

Detailed of the Budget:

Particulars BDT Doctor's salary- 1x6 months x 20000 120,000/- Data entry computer personel (Research associate's monthly salary 10000/-X 6) 60,000/= Specialist visit (Approximate) 40,000/= Investigations (Approximate) 1,00000/- Statistical analysis 15,000/= Stationary cost 10,000/= Others 5,000/= Total in Amount 3,50,000/=

I. FUNDING:

Contribution from researchers

J. OUTCOME:

At the end of study, we will be able to assess long-term effects of COVID-19 in patients of southern part of Bangladesh and to know its incidence. It will be possible to compare this with other studies in Bangladesh and other countries.

K. CONFLICTS OF INTEREST:

The investigator will not have any salary for himself from the fund. The salary will be provided to doctor, research associates and statistician.

03

Conditions studied

  • To Assess Long-term Effects of COVID-19 in Patients Who Were Affected With COVID -19

Browse trials for

Keywords

  • long-term effects
  • COVID-19
  • RT-PCR +vE
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

COVID -19 (RT-PCR +ve) patients from 1st July to 30th December, 2020 recorded in PCR Lab of Sher-E-Bangla Medical College Hospital, Barishal.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • COVID-19 (RT-PCR +ve) patients age 20 years and above
  • Those patients whose mobile numbers are recorded in the register
  • Those patients who/their attendants are available on mobile phone

Exclusion criteria

Exclusion Criteria:

  • Persons below 20 years of age
  • Those patients whose mobile numbers are not recorded in the register
  • Those patients who/their attendants are not available on mobile phone
  • Those who died by this time from causes unrelated to COVID-19
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
302 participants (estimated)
Patient registry
No

Groups and cohorts

  • COVID-19 (RT-PCR +ve) patients

    Diagnostic Test: RT-PCR

Interventions

  • Diagnostic testRT-PCR

    COVID 19 diagonostic test

06

What researchers measure

Primary outcomes

  1. Assessment of long-term effects (complications) of COVID-19 in the southern part of Bangladesh

    At the end of study, we will be able to assess long-term effects of COVID-19 in patients of southern part of Bangladesh and to know its incidence.

    Time frame: 6 Months

07

Study locations

1 of 1 sites recruiting
  • HN Sarker
    Barisal, 1207, Bangladesh
    Recruiting
    • HN Sarker · Contact01715079037
08

References and documents

Publications

  • WHO, Coronavirus disease 2019 (COVID-19) situation report, 7 May 2021, WHO Bull, 2021
  • de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016 Aug;14(8):523-34. doi: 10.1038/nrmicro.2016.81. Epub 2016 Jun 27. PubMed 27344959 ↗
  • Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Apr;20(4):425-434. doi: 10.1016/S1473-3099(20)30086-4. Epub 2020 Feb 24. PubMed 32105637 ↗

Individual participant data

Plan to share: Undecided — Decide later.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2021 (actual). Primary completion is estimated for Oct 2021, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2021
First posted
Aug 3, 2021
StartActual
Jul 1, 2021
Primary completionEst.
Oct 30, 2021
CompletionEst.
Dec 30, 2021
Last update
Aug 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04987736
Lead sponsor
Sher-E-Bangla Medical College
Responsible party
Harendra Nath Sarker (Professor, Sher-E-Bangla Medical College) — Principal investigator
First posted
Aug 3, 2021
Start date
Jul 1, 2021
Primary completion
Oct 30, 2021 (estimated)
Completion
Dec 30, 2021 (estimated)
Last update
Aug 3, 2021

Study contacts

HN Sarker, MBBS
Contact
hnsarker@gmail.com
+8801715079037

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion